BayWa’s Creditor Standoff and Asset Sale Saga Define Pivotal Year

The fate of German agricultural and energy group BayWa rests on a precarious convergence of events slated for the final quarter of 2026. Two critical milestones—the long-delayed audited financial statements for 2025 and a crucial agreement with creditor banks—are expected to arrive simultaneously, determining the company’s capacity to continue its restructuring. This timeline leaves investors navigating in the dark, with the share price down nearly 20% since the start of the year and trading roughly 21% below its 200-day moving average.

Central to the immediate financial maneuvering is an expected liquidity injection this month. From the completed sale of its Cefetra unit, BayWa anticipates a payment of 45 million euros by April 30, supplemented by approximately 62 million euros from the repayment of shareholder loans. The deconsolidation of Cefetra is also projected to reduce group bank debt by more than 600 million euros. This cash flow is a key bargaining chip as management seeks to extend a vital forbearance agreement with its core lenders, including DZ Bank and HVB, until autumn 2026. Without this extension, the company lacks the operational foundation to proceed.

The broader restructuring plan, however, remains far off track. The total debt reduction target stands at four billion euros by 2028. To date, transactions including the Cefetra sale have secured only 1.3 billion euros in liability reductions. A major setback was the collapse of a plan to sell a 51% stake in its renewable energy subsidiary, BayWa r.e., which could have fetched up to 1.7 billion euros. That deal failed after U.S. subsidies for renewable energy were withdrawn in early 2025.

This financial strain is compounded by a severe legal and regulatory crisis. BayWa terminated its relationship with auditor PricewaterhouseCoopers (PwC), alleging the firm failed to disclose existential risks in the 2023 consolidated financial statements. These undisclosed risks included conditions of a billion-euro credit line and refinancing risks for a 500-million-euro bond and short-term notes worth 632 million euros. Germany’s financial watchdog, BaFin, reprimanded BayWa in October 2025 for inadequate risk disclosure and has an ongoing audit of the statements. The auditor oversight body, Apas, has initiated professional disciplinary proceedings against PwC.

Should investors sell immediately? Or is it worth buying BayWa?

In a separate but parallel development, the Munich I public prosecutor’s office is investigating former executives, including ex-CEO Marcus Pöllinger, on suspicion of breach of trust, with raids conducted in January. All accused are presumed innocent. Meanwhile, law firm TILP is preparing damages claims for shareholders who purchased BayWa stock between January 2022 and January 2026.

Amid this turmoil, the sale of a key asset is progressing but faces its own hurdles. In March 2026, BayWa hired Goldman Sachs to manage the sale of its roughly 74% stake in New Zealand fruit grower T&G Global. The company, known for apple brands like Envy and Jazz marketed in over 60 countries, reported 2024 revenue of 1.3 billion US dollars and a net profit of 16 million US dollars. Specialized private equity firms such as Roc Partners, Paine Schwartz, and Hancock are seen as potential buyers, with an expected proceeds of around 300 million euros. The process is complicated by minority shareholder Joy Wing Mau Group from Hong Kong, which holds nearly a 20% stake and is reported to be making the sale more difficult. T&G Global has stated no final decision has been made.

Internally, BayWa has tightened controls. The supervisory board has lowered the approval threshold for transactions from 200 million to 50 million euros. Furthermore, a rotating election system will be introduced from 2028, with two members up for re-election annually and board terms shortened from five to four years.

With the 2026 annual forecast withdrawn and the adjusted EBITDA target for 2027 lowered to around 140 million euros—a plan that includes cutting 1,300 jobs—the path forward is narrow. The share price, trading about 37% below its 52-week high of 21.50 euros, reflects profound uncertainty. For now, the market awaits the twin signals due in late 2026 that will either illuminate a path to survival or confirm a deeper crisis.